May 30, 2022
Dr. Phil Kantoff is the CEO and Co-Founder and Alex Brown is the COO of Convergent Therapeutics which is developing the next generation of targeted therapies to treat cancer. Drawing on insights from developments in radiopharmaceuticals, Convergent focuses on radioantibodies that are radioisotopes attached to antibodies directed to treat prostate cancer.
Phil explains, "Antibodies will recognize surface molecules on cancer cells and they can be linked to radioisotopes. We are focused on an isotope known as Actinium-225, which is an important radioisotope because it's different than isotopes that have been previously used, it's an alpha-emitting radiopharmaceutical. Alpha particles are much larger, they're much more powerful, and they travel a shorter distance. You can deliver a very powerful, very targeted therapy to cancer."
"We have clinical trials that are taking place right now that are showing remarkable activity using the combination of the directed antibody against prostate cancer cells, specifically prostate-specific membrane antigen coupled to this isotope, Actinium-225."
Alex continues, "Our radioantibodies, which is what we're talking about here, are novel enough that there are few if any, examples of marketed products out there. It's a field that's emerging, so aside from having the experience in antibody development and commercialization, some of this is new to our team as well as to others."
@ConvergentRx @DrPhilKantoff #ProstateCancer #Radiopharmaceuticals #PSMA #Radioantibody #RadioLingandTherapy #Oncology #Biotechnology
